Thomas Prebet

Associate Professor Adjunct · Yale-New Haven Hospital

Credentials: · · · ·

History

Yale-New Haven Hospital · Yale School of Medicine
Present

Johns Hopkins University School of Medicine
2009–2010
Johns Hopkins University
2007–2010
Centre de Recherche en Cancerologie
2006–2009
Centre de Recherche en Cancerologie
2009
Claude Bernard University
2004–2005
Claude Bernard University
2005
University Hospitals of Lyon
2001–2004
Johns Hopkins University
Claude Bernard University
1996–2000

Research

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
British Journal of Haematology · 2009 · 481 citations
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Journal of Clinical Oncology · 2011 · First of 14 authors · 408 citations
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy
Blood · 2016 · 378 citations

SG
Steven Gore
32 papers
Amer Zeidan
28 papers · 4 as a fellow
RK
Rami Komrokji
14 papers
Mikkael Sekeres
12 papers
Nikolai Podoltsev
12 papers
Gail Roboz
11 papers
Amir Fathi
8 papers
MT
Martin Tallman
8 papers
Maximilian Stahl
8 papers
Mark Litzow
7 papers
Jan Bewersdorf
6 papers · 5 as a resident
Namrata Chandhok
6 papers · 5 as a fellow

Clinical trials

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Principal investigator · Withdrawn · Phase 2
Yale University
2020–2023
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
Principal investigator · Withdrawn · Phase 1, Phase 2
Yale University
2019–2021
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
Yale University
2016–2021
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Principal investigator · Completed · Phase 1
Groupe Francophone des Myelodysplasies
2015–2018